Fondation du centre Pluridisciplinaire d'Oncologie (CePO)
Welcome,         Profile    Billing    Logout  
 5 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Peters, Solange
MERMAID-1, NCT04385368 / 2020-000556-35: Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Hourglass Jan 2024 - Dec 2024 : Results from MERMAID-1 trial for stage II-III NSCLC
Jan 2023 - Dec 2024: Regulatory submission for adjuvant NSCLC (based on MERMAID-1 trial)
Completed
3
89
Europe, Canada, Japan, US, RoW
Durvalumab + SoC chemotherapy, MEDI4736, Placebo + SoC chemotherapy, Placebo
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/23
08/23
ADOPT-lung, NCT06284317: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Recruiting
3
290
Europe, RoW
Adjuvant durvalumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non Small Cell Lung Cancer
10/29
03/30
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
STIMULI, NCT02046733 / 2013-002609-78: Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

Completed
2
222
Europe, RoW
Ipilimumab, Yervoy, Nivolumab, Opdivo
ETOP IBCSG Partners Foundation, Intergroupe Francophone de Cancerologie Thoracique, Ludwig Center for Cancer Research of Lausanne, Frontier Science Foundation, Hellas, Bristol-Myers Squibb
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
05/20
02/22
BOOSTER, NCT03133546 / 2016-002029-12: Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

Checkmark From BOOSTER trial in combination wit Avastin for NSCLC
May 2021 - May 2021: From BOOSTER trial in combination wit Avastin for NSCLC
Completed
2
155
Europe, RoW
Osimertinib, Tagrisso, Bevacizumab, Avastin
ETOP IBCSG Partners Foundation, AstraZeneca, Hoffmann-La Roche
Non Small Cell Lung Cancer Metastatic
02/21
02/24
NIVOTHYM, NCT03134118 / 2015-005504-28: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma

Active, not recruiting
2
55
Europe
Nivolumab, BMS-936558-01
European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation
Thymoma Type B3, Thymic Carcinoma
12/23
07/24
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
CHESS, NCT03965468 / 2018-003011-22: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Recruiting
2
96
Europe
Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
08/26
12/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Completed
1/2
109
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
10/24
10/24
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
1006
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
08/26
05/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Peters, Solange
MERMAID-1, NCT04385368 / 2020-000556-35: Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Hourglass Jan 2024 - Dec 2024 : Results from MERMAID-1 trial for stage II-III NSCLC
Jan 2023 - Dec 2024: Regulatory submission for adjuvant NSCLC (based on MERMAID-1 trial)
Completed
3
89
Europe, Canada, Japan, US, RoW
Durvalumab + SoC chemotherapy, MEDI4736, Placebo + SoC chemotherapy, Placebo
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/23
08/23
ADOPT-lung, NCT06284317: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Recruiting
3
290
Europe, RoW
Adjuvant durvalumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non Small Cell Lung Cancer
10/29
03/30
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
STIMULI, NCT02046733 / 2013-002609-78: Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

Completed
2
222
Europe, RoW
Ipilimumab, Yervoy, Nivolumab, Opdivo
ETOP IBCSG Partners Foundation, Intergroupe Francophone de Cancerologie Thoracique, Ludwig Center for Cancer Research of Lausanne, Frontier Science Foundation, Hellas, Bristol-Myers Squibb
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
05/20
02/22
BOOSTER, NCT03133546 / 2016-002029-12: Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

Checkmark From BOOSTER trial in combination wit Avastin for NSCLC
May 2021 - May 2021: From BOOSTER trial in combination wit Avastin for NSCLC
Completed
2
155
Europe, RoW
Osimertinib, Tagrisso, Bevacizumab, Avastin
ETOP IBCSG Partners Foundation, AstraZeneca, Hoffmann-La Roche
Non Small Cell Lung Cancer Metastatic
02/21
02/24
NIVOTHYM, NCT03134118 / 2015-005504-28: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma

Active, not recruiting
2
55
Europe
Nivolumab, BMS-936558-01
European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation
Thymoma Type B3, Thymic Carcinoma
12/23
07/24
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Recruiting
2
186
Europe, Canada, US, RoW
inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta
iTeos Therapeutics, iTeos Belgium SA
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
04/25
05/25
CHESS, NCT03965468 / 2018-003011-22: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Recruiting
2
96
Europe
Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
08/26
12/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Completed
1/2
109
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
10/24
10/24
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
1006
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
08/26
05/28

Download Options